Alexion Pharmaceuticals (NASDAQ:ALXN) has coverage initiated with a Outperform rating and $161.00 price target

ME Staff
-
0

Analyst Ratings For Alexion Pharmaceuticals (NASDAQ:ALXN)

Today, Raymond James initiated coverage on Alexion Pharmaceuticals (NASDAQ:ALXN) with a Outperform with a price target of $161.00.

There are 13 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Alexion Pharmaceuticals (NASDAQ:ALXN) is Buy with a consensus target price of $164.00 per share, a potential 15.81% upside.

Some recent analyst ratings include

  • 4/10/2019-Alexion Pharmaceuticals (NASDAQ:ALXN) has coverage initiated with a Outperform rating and $161.00 price target
  • 3/27/2019-Alexion Pharmaceuticals (NASDAQ:ALXN) had its Outperform ➝ Outperform rating reiterated by Royal Bank of Canada with a $186.00 price target
  • 3/21/2019-Alexion Pharmaceuticals (NASDAQ:ALXN) had its Neutral ➝ Neutral rating reiterated by Guggenheim with a $135.00 price target
  • 3/13/2019-Alexion Pharmaceuticals (NASDAQ:ALXN) had its Buy rating reiterated by Cowen with a $165.00 price target
  • 1/22/2019-Alexion Pharmaceuticals (NASDAQ:ALXN) had its Buy rating reiterated by Credit Suisse Group with a $156.00 price target
  • On 2/14/2019 Daniel Bazarko, CAO, sold 2,000 with an average share price of $126.00 per share and the total transaction amounting to $252,000.00.
  • On 12/31/2018 Ludwig Hantson, CEO, sold 3,244 with an average share price of $95.85 per share and the total transaction amounting to $310,937.40.
  • On 12/31/2018 Ludwig Hantson, CEO, sold 3,244 with an average share price of $95.85 per share and the total transaction amounting to $310,937.40.
  • On 11/28/2018 Indrani Lall Franchini, EVP, sold 2,605 with an average share price of $118.13 per share and the total transaction amounting to $307,728.65.
  • On 7/10/2018 Paul J Clancy, CFO, sold 5,241 with an average share price of $131.11 per share and the total transaction amounting to $687,147.51.
  • On 6/8/2018 John J Orloff, EVP, sold 2,115 with an average share price of $118.53 per share and the total transaction amounting to $250,690.95.
  • On 4/30/2018 Christopher J Coughlin, Director, bought 10,000 with an average share price of $120.79 per share and the total transaction amounting to $1,207,900.00.

About Alexion Pharmaceuticals (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 (SYNT001), which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain (AL) amyloidosis; and partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Recent Trading Activity for Alexion Pharmaceuticals (NASDAQ:ALXN)
Shares of Alexion Pharmaceuticals closed the previous trading session at 141,60 up +3,95 2,87 % with 141.82 shares trading hands.